This report is built using data and information sourced from Global Markets Direct's proprietary databases, Mymetics Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Mymetics Corporation and industry-specific third party sources, put together by Global Markets Direct's team.
------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/
------------------------------------------------------------
Scope
* Mymetics Corporation - Brief Mymetics Corporation overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Mymetics Corporation human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Mymetics Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Mymetics Corporation's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.
Reasons to buy
* Evaluate Mymetics Corporation's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Mymetics Corporation in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Mymetics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Mymetics Corporation.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Mymetics Corporation and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Mymetics Corporation;
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Mymetics Corporation Snapshot
Mymetics Corporation Overview
Key Information
Key Facts
Mymetics Corporation - Research and Development Overview
Key Therapeutic Areas
Mymetics Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Mymetics Corporation - Pipeline Products Glance
Mymetics Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mymetics Corporation - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mymetics Corporation - Drug Profiles
HSV Vaccine
Product Description
Mechanism of Action
R&D Progress
Intra Nasal Influenza Vaccine
Product Description
Mechanism of Action
R&D Progress
MYM-V101
Product Description
Mechanism of Action
R&D Progress
PEV3
Product Description
Mechanism of Action
R&D Progress
Vaccine For RSV
Product Description
Mechanism of Action
R&D Progress
Mymetics Corporation - Pipeline Products by Route of Administration
Mymetics Corporation - Recent Pipeline Updates
Mymetics Corporation - Dormant Projects
Mymetics Corporation - Company Statement
Mymetics Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Mymetics Corporation, Recent Developments
Mymetics Corporation-
Oct 20, 2009: Mymetics Corporation Presents Ground Breaking Results With Preventative HIV Vaccine At The World AIDS Vaccine Congress In Paris
Feb 09, 2009: Mymetics Corporation Announces Success of Its Preventive Vaccine Against Hiv/Aids and Commencement of European Phase 1 Human Clinical Trials
Financial Deals Landscape
Mymetics Corporation, Deals Summary
Mymetics Corporation, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Mymetics Acquires Preventive Malaria Vaccine From Pevion Biotech
Licensing Agreements
Mymetics Enters Into Licensing Agreement With INSERM
Mymetics Enters Into Licensing Agreement With PX Therapeutics
Mymetics Enters Into Licensing Agreement With Pevion Biotech
Equity Offering
Mymetics Announces Private Placement Of $49 Million
Mymetics Completes Private Placement Of $0.15 Million
Mymetics Completes Private Placement Of $0.78 Million
Mymetics Completes Private Placement Of $0.7 Million
Mymetics Completes Private Placement Of $1.5 million
Debt Offering
Mymetics Completes Private Placement Of 10% Convertible Notes Of $2.34 Million
Acquisition
Mymetics Acquires Virosome Biologicals
Norwood Immunology Acquires Bestewil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Mymetics Corporation, Key Information
Mymetics Corporation, Key Facts
Mymetics Corporation - Pipeline by Indication, 2012
Mymetics Corporation - Pipeline by Stage of Development, 2012
Mymetics Corporation - Monotherapy Products in Pipeline, 2012
Mymetics Corporation - Phase II, 2012
Mymetics Corporation - Phase I, 2012
Full Table of Contents is available at:
-- http://www.fastmr.com/
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.
